Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomx Inc PHGE

Alternate Symbol(s):  PHGE.U | PHGEW

Healthcare Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer... see more

Recent & Breaking News (NYSEAM:PHGE)

BiomX Announces the Appointment of Susan Blum to its Board of Directors

GlobeNewswire 1 day ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

GlobeNewswire April 4, 2024

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire April 3, 2024

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

GlobeNewswire March 27, 2024

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

GlobeNewswire March 18, 2024

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating BiomX Inc. Buyout

Newsfile March 8, 2024

Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics

PR Newswire March 7, 2024

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

GlobeNewswire March 6, 2024

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

GlobeNewswire January 4, 2024

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

GlobeNewswire November 30, 2023

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

GlobeNewswire November 29, 2023

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 14, 2023

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

GlobeNewswire October 27, 2023

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

GlobeNewswire October 18, 2023

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

GlobeNewswire October 4, 2023

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

GlobeNewswire September 7, 2023

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 9, 2023

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

GlobeNewswire August 2, 2023

NYSE American Initiates Delisting Proceedings for BiomX Warrants

GlobeNewswire June 8, 2023